A nonpeptide angiotensin II receptor antagonist which selectively and insurmountably inhibits the angiotensin II AT1 receptor subtype (Ki = 3.7 nM), a partial agonist of PPARγ, activating the receptor to 25-30% of that produced by the full agonist rosiglitazone (EC50 = 4.5 µM), potently reduces blood pressure
